Comments
Glenmark Pharmaceuticals has filed an application in Netherlands for human trials on its molecule ‘GRC 17536’, which aims to treat pain and respiratory disorders.
The company has completed animal trials on its novel chemical entity (NCE) GRC 17536 and has filed the Phase I application for first-in-man trial in Netherlands, Glenmark Pharmaceuticals said in a filing to the Bombay Stock Exchange.
“We are excited that our TRPA1 discovery programme is moving forward to human trials. This is another potential first-in-class molecule indicated for both pain and respiratory conditions,” the company CEO and Managing Director, Mr Glenn Saldanha, said.
The company said that the total market for asthma and chronic lung disease is about $30 billion and for osteoarthritis and neuropathic pain, it is nearly $10 billion.
“There is a huge unmet medical need in both therapeutic areas globally. GRC 17536 is highly selective even when compared with other TRPs and can be administered orally,” he added.
Meanwhile, the company shares were today trading at Rs 291.30 in the afternoon trade on the BSE, up 0.92 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.